Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

| Medlab Clinical Limited |

ABN

| 51 169 149 071 |

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

<table>
<thead>
<tr>
<th>1</th>
<th>Class of securities issued or to be issued</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Number of securities issued or to be issued (if known) or maximum number which may be issued</td>
<td>N/A</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
3 Principal terms of the securities (e.g. if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion)

N/A

4 Do the securities rank equally in all respects from the issue date with an existing class of quoted securities?

If the additional securities do not rank equally, please state:
- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

N/A

5 Issue price or consideration

N/A

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

N/A
| 6a | Is the entity an eligible entity that has obtained security holder approval under rule 7.1A? | N/A |
| 6b | The date the security holder resolution under rule 7.1A was passed | N/A |
| 6c | Number of securities issued without security holder approval under rule 7.1 | N/A |
| 6d | Number of securities issued with security holder approval under rule 7.1A | N/A |
| 6e | Number of securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | N/A |
| 6f | Number of securities issued under an exception in rule 7.2 | N/A |
| 6g | If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. | N/A |
| 6h | If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/A |

+ See chapter 19 for defined terms.
6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

N/A

7 *Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

N/A

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

<table>
<thead>
<tr>
<th>Number</th>
<th>*Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>178,705,000</td>
<td>Fully paid ordinary shares</td>
</tr>
</tbody>
</table>
Number and class of all securities not quoted on ASX (including the securities in section 2 if applicable)

<table>
<thead>
<tr>
<th>Number</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>11,000,000</td>
<td>Unlisted options exercisable at $0.30, expiring on 30 June 2019</td>
</tr>
<tr>
<td>1,541,725</td>
<td>Unlisted options exercisable at $0.30, expiring on 30 June 2020</td>
</tr>
</tbody>
</table>

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

| 11 | N/A |

Part 2 - Pro rata issue

<table>
<thead>
<tr>
<th>11</th>
<th>Is security holder approval required?</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities

34 Type of +securities
(tick one)

(a) ☐ +Securities described in Part 1

(b) ☑ All other +securities
   Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 ☐ If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 ☐ If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
   1 - 1,000
   1,001 - 5,000
   5,001 - 10,000
   10,001 - 100,000
   100,001 and over

37 ☐ A copy of any trust deed for the additional +securities
Entities that have ticked box 34(b)

38 Number of +securities for which +quotation is sought
   80,521,547

39 +Class of +securities for which quotation is sought
   Fully paid ordinary shares

40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?
   Yes

   If the additional +securities do not rank equally, please state:
   • the date from which they do
   • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
   • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now
   End of restriction period in July 2017

   Example: In the case of restricted securities, end of restriction period

   (if issued upon conversion of another +security, clearly identify that other +security)

42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

<table>
<thead>
<tr>
<th>Number</th>
<th>+Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>178,705,000</td>
<td>Fully paid ordinary shares</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
Quotation agreement

1 Quotation of our additional securities is in ASX’s absolute discretion. ASX may quote the securities on any conditions it decides.

2 We warrant the following to ASX.
   • The issue of the securities to be quoted complies with the law and is not for an illegal purpose.
   • There is no reason why those securities should not be granted quotation.
   • An offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
      Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
   • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any securities to be quoted and that no-one has any right to return any securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the securities be quoted.
   • If we are a trust, we warrant that no person has the right to return the securities to be quoted under section 1019B of the Corporations Act at the time that we request that the securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before quotation of the securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: 

Company Secretary

Date: 21 July 2017

Print name: Alan Dworkin